File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1146/annurev-pharmtox-032322-093904
- Scopus: eid_2-s2.0-85146741245
- PMID: 36100222
- WOS: WOS:000915418300019
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications
Title | Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications |
---|---|
Authors | |
Keywords | agonistic antibodies Fibroblast growth factors metabolic complications obesity protein therapeutics |
Issue Date | 1-Jan-2023 |
Publisher | Annual Reviews |
Citation | Annual Review of Pharmacology and Toxicology, 2023, v. 63, p. 359-382 How to Cite? |
Abstract | The fibroblast growth factor (FGF) family, which comprises 22 structurally related proteins, plays diverse roles in cell proliferation, differentiation, development, and metabolism. Among them, two classical members (FGF1 and FGF4) and two endocrine members (FGF19 and FGF21) are important regulators of whole-body energy homeostasis, glucose/lipid metabolism, and insulin sensitivity. Preclinical studies have consistently demonstrated the therapeutic benefits of these FGFs for the treatment of obesity, diabetes, dyslipidemia, and nonalcoholic steatohepatitis (NASH). Several genetically engineered FGF19 and FGF21 analogs with improved pharmacodynamic and pharmacokinetic properties have been developed and progressed into various stages of clinical trials. These FGF analogs are effective in alleviating hepatic steatosis, steatohepatitis, and liver fibrosis in biopsy-confirmed NASH patients, whereas their antidiabetic and antiobesity effects are mild and vary greatly in different clinical trials. This review summarizes recent advances in biopharmaceutical development of FGF-based therapies against obesity-related metabolic complications, highlights major challenges in clinical implementation, and discusses possible strategies to overcome these hurdles. |
Persistent Identifier | http://hdl.handle.net/10722/338260 |
ISSN | 2023 Impact Factor: 11.2 2023 SCImago Journal Rankings: 3.957 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, LG | - |
dc.contributor.author | Yang, RY | - |
dc.contributor.author | Geng, LL | - |
dc.contributor.author | Xu, AM | - |
dc.date.accessioned | 2024-03-11T10:27:30Z | - |
dc.date.available | 2024-03-11T10:27:30Z | - |
dc.date.issued | 2023-01-01 | - |
dc.identifier.citation | Annual Review of Pharmacology and Toxicology, 2023, v. 63, p. 359-382 | - |
dc.identifier.issn | 0362-1642 | - |
dc.identifier.uri | http://hdl.handle.net/10722/338260 | - |
dc.description.abstract | The fibroblast growth factor (FGF) family, which comprises 22 structurally related proteins, plays diverse roles in cell proliferation, differentiation, development, and metabolism. Among them, two classical members (FGF1 and FGF4) and two endocrine members (FGF19 and FGF21) are important regulators of whole-body energy homeostasis, glucose/lipid metabolism, and insulin sensitivity. Preclinical studies have consistently demonstrated the therapeutic benefits of these FGFs for the treatment of obesity, diabetes, dyslipidemia, and nonalcoholic steatohepatitis (NASH). Several genetically engineered FGF19 and FGF21 analogs with improved pharmacodynamic and pharmacokinetic properties have been developed and progressed into various stages of clinical trials. These FGF analogs are effective in alleviating hepatic steatosis, steatohepatitis, and liver fibrosis in biopsy-confirmed NASH patients, whereas their antidiabetic and antiobesity effects are mild and vary greatly in different clinical trials. This review summarizes recent advances in biopharmaceutical development of FGF-based therapies against obesity-related metabolic complications, highlights major challenges in clinical implementation, and discusses possible strategies to overcome these hurdles. | - |
dc.language | eng | - |
dc.publisher | Annual Reviews | - |
dc.relation.ispartof | Annual Review of Pharmacology and Toxicology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | agonistic antibodies | - |
dc.subject | Fibroblast growth factors | - |
dc.subject | metabolic complications | - |
dc.subject | obesity | - |
dc.subject | protein therapeutics | - |
dc.title | Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1146/annurev-pharmtox-032322-093904 | - |
dc.identifier.pmid | 36100222 | - |
dc.identifier.scopus | eid_2-s2.0-85146741245 | - |
dc.identifier.volume | 63 | - |
dc.identifier.spage | 359 | - |
dc.identifier.epage | 382 | - |
dc.identifier.eissn | 1545-4304 | - |
dc.identifier.isi | WOS:000915418300019 | - |
dc.publisher.place | PALO ALTO | - |
dc.identifier.issnl | 0362-1642 | - |